<DOC>
	<DOCNO>NCT02306070</DOCNO>
	<brief_summary>HCV antiviral therapy evolve rapidly recent year access medication improve . While SVR associate improved liver outcome , rate liver fibrosis regression SVR variable predictor regression well establish . In addition , achieve SVR patient cirrhosis necessarily prevent decompensation eliminate risk HCC . A well understanding role insulin resistance impair glucose metabolism outcome HCV patient achieve SVR need . Identifying target potentially modifiable risk factor IR may significant importance prevent progression promote regression liver fibrosis , reduce mortality improve outcome HCV-HIV co-infected HCV-mono-infected patient . This propose pilot study first evaluate role Metformin liver fibrosis HCV-HIV co-infected HCV mono-infected patient IR receive DAA HCV treatment . If Metformin effective reduce liver fibrosis patient population , represent well-tolerated , easy administer , inexpensive therapy protect negative HCV outcomes . This study also opportunity evaluate impact insulin resistance hyperglycemia viral clearance HCV-infected patient treat interferon-free regimen . In addition , study explore relationship HCV , insulin resistance AFP level .</brief_summary>
	<brief_title>Improving Outcomes With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Male female , 18 79 year old inclusive 2 . Provision inform consent 3 . Documented history chronic HCV RNA infection 4 . Intending start 812 week IFNfree HCV antiviral therapy 5 . If HIVinfected HIV antiretroviral therapy , CD4 count least &gt; 200 6 . Insulin resistance determine HOMAIR &gt; 2.0 screen 7 . Evidence fibrosis FibroScanÂ® &gt; 8.0 kPa , OR liver biopsy score &gt; 2 ( BattsLudwig System ) [ 55 ] ( within 2 year ) 1 . Pregnant , suspect pregnant , plan become pregnant breastfeed 2 . Chronic HBV infection 3 . HbA1c &gt; 8.0 4 . Use immune suppress medication 5 . Active malignancy 6 . Current previous treatment Metformin , oral diabetes medication , insulin 7 . Preexisting diabetes ( type 1 , type 2 gestational diabetes ) 8 . Clinical evidence decompensated cirrhosis ( ascites , esophageal varix , hepatic encephalopathy , hepatocellular carcinoma ) 9 . Presence renal impairment renal function know , also patient serum creatinine level upper limit normal range . Renal disease renal dysfunction ( e.g. , suggest serum creatinine level &gt; = 136 umol/L ( male ) , &gt; = 124 umol/L ( female ) abnormal creatinine clearance ( 60 mL/min ) ) 10 . History congestive heart failure require pharmacologic therapy 11 . Wilson 's disease 12 . Alpha1 antitrypsin 13 . Hemochromatosis 14 . Biliary Cirrhosis 15 . Alcohol consumption &gt; 50 g / day average ( see Appendix B conversion volume ) 16 . Participation clinical investigation study 17 . History lactic acidosis , irrespective precipitating factor Active illicit drug use stable health illness exclusionary assume unlikely compromise study adherence protocol study drug . In HIVinfected participant , HIV antiretroviral use suppress HIV viral load require participation . HCV antiviral therapy withheld participant eligible desire start treatment . If HCV treatment anticipate start 48week period assessment , participant enrol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>